Globus Medical (GMED) Following Guidance Cut Is The Selloff A Buying Opportunity

Globus Medical stock moves after guidance cut and acquisition push

Globus Medical (GMED) has been in focus after third quarter 2026 results showed slightly softer sales, a trim to full year revenue guidance, and fresh commentary on acquisitions and capital deployment.

The sharp move in Globus Medical shares after the Q3 release fits a broader pattern of pressure this year, with the 1 day share price return of down 12.76% and year to date share price return of down 18.61% reflecting investor concern around the guidance cut and Nevro softness. Short term momentum has faded, with the 7 day share price return down 8.97% and 90 day share price return down 17.53%. The longer history looks different, as the 3 year total shareholder return is up 60.89%, despite a 1 year total shareholder return of down 15.31% and a 5 year total shareholder return of down 3.71%.

Scan Globus Medical alongside other pressured medical device names and see which ones screen best on fundamentals in our curated list of solid balance sheet and fundamentals (25 results).

Globus Medical still appears to be a robust business on the income statement, even after the revenue miss, guidance cut, and Nevro drag. The real issue for investors now is how that quality lines up with today’s share price.

Most Popular Narrative: 26% Undervalued

On the analyst consensus Narrative on Simply Wall St, Globus Medical is assessed with a fair value of $96.54 against a last close of $71.05, which points to a material gap that the Narrative links to earnings power, cash returns, and the robotics platform rather than short term sentiment after the guidance cut.

The main thing that has to go right is continued execution on margin expansion from manufacturing efficiencies and M&A synergies, while keeping growth on track in robotics, trauma, international spine and neuromodulation despite volatility in Enabling Technologies and Nevro revenue.

See why 21 investors see Globus Medical as 26% undervalued.

Result: Fair Value of $96.54 (UNDERVALUED)

Still, the narrative around Globus Medical can shift quickly if Enabling Technologies revenue volatility persists or if the Nevro reset drags on longer than analysts expect.

Find out about the key risks to this Globus Medical narrative.

Next Steps

Sentiment around Globus Medical is mixed right now, which makes this a good moment to move quickly and test the numbers yourself. If you want to see what optimism is built on, take a closer look at the 5 key rewards.

Looking for more Globus Medical sized opportunities?

If you stop with Globus Medical, you only see one angle. Broaden your watchlist with fresh ideas that could fit very different roles in your portfolio.

• Target resilient compounding potential by scanning a curated set of quality companies that still trade below their estimated worth through the 40 high quality undervalued stocks.
• Strengthen your income stream by focusing on robust payers with higher yields using the 7 dividend fortresses.
• Reduce portfolio stress by concentrating on businesses that pair healthy finances with lower risk profiles through the 31 resilient stocks with low risk scores.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com